 | | Vol. 12.35 – 10 September, 2020 |
| |
|
|
| Researchers showed that centrosome depletion induced synthetic lethality in cancer cells that contained the 17q23 amplicon, a recurrent copy number aberration that defined about 9% of all primary breast cancer tumors and was associated with high levels of genomic instability.
[Nature] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Low tripartite motif-containing 37 (TRIM37) levels accelerated acentrosomal spindle assembly and improved proliferation following polo-like kinase 4 (PLK4) inhibition, whereas high TRIM37 levels inhibited acentrosomal spindle assembly, leading to mitotic failure and cessation of proliferation.
[Nature] |
|
|
|
| Investigators demonstrated that breast cancer-derived extracellular vesicles activated liver sinusoidal endothelial cells in the liver-chip, inducing endothelial to mesenchymal transition and destruction of vessel barriers.
[ACS Nano] |
|
|
|
| Scientists found that glioma-associated oncogene family zinc finger 1was activated in TNBC cells in response to ionizing radiation (IR) and localized to ribosomal DNA (rDNA) sequences in response to both global double-strand breaks (DSBs) generated by IR and site-specific DSBs in rDNA.
[Nucleic Acids Research] |
|
|
|
| Researchers demonstrated that meR342-EZH2 decreased enhancer of zeste homolog 2 (EZH2) target gene expression, but increased breast cancer cell epithelial–mesenchymal transition, invasion and metastasis.
[Cell Death & Differentiation] |
|
|
|
| Mechanistic analyses determined that hTERT promoter-driven VP16-GAL4-WPRE integrated systemic amplifier delivery composite vector-circular RNA RGPD6 (TV-circRGPD6) suppressed breast cancer stem cell-mediated metastasis via miR-26b/YAF2 axis.
[Molecular Therapy] |
|
|
|
| Investigators discovered an alternative “migration-by-tethering” mechanism through which cancer cells gained momentum to migrate by adhering to mesenchymal stem cells or osteoblasts.
[npj Breast Cancer] |
|
|
|
| To uncover the relation between oncogene expression, replication stress, and clinical features of breast cancer subgroups, researchers immunohistochemically analyzed the expression of a panel of oncogenes and markers of replication stress in breast tumor tissues prior to treatment.
[npj Breast Cancer] |
|
|
|
| Scientists investigated the effectiveness of a novel combination treatment with the platelet-derived growth factor receptor β aptamer and anti-programmed cell death-ligand 1 monoclonal antibody in TNBC.
[Journal of Experimental & Clinical Cancer Research] |
|
|
|
| Investigators revealed that prostate cancer-associated transcript 6 (PCAT6) boosted TNBC proliferation, migration, and angiogenesis both in vitro and in vivo.
[Cell Death & Disease] |
|
|
|
| Ectopic expression of miR-210-3p enhanced glucose uptake, lactate production, extracellular acidification rate, colony formation ability, and reduced serum starvation-induced cell apoptosis.
[Cell Death & Disease] |
|
|
|
| Scientists analyzed the in vivo molecular response to proton therapy and its efficacy in a MDA-MB-231 TNBC xenograft model.
[Cancers] |
|
|
|
|
| Investigators outline the prospects and directions for a better understanding and re-purposing of metformin as an anti-cancer/chemo-sensitizing drug in the treatment of breast cancer.
[Cancers] |
|
|
|
| The authors review the function of the phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway and the various classes of PI3K pathway inhibitors that have been developed to disrupt this pathway signaling for the treatment of hormone-receptor-positive breast cancer.
[Drugs] |
|
|
|
| Investigators summarize the general understandings of miRNA-regulated biological processes in breast cancer, particularly focused on the role of miRNA in cisplatin resistance/sensitivity.
[Anti-Cancer Agents in Medicinal Chemistry] |
|
|
|
|
| Knight Therapeutics Inc. announced the filing of NERLYNX®for receptor tyrosine-protein kinase erbB-2-positive metastatic breast cancer in Canada.
[Knight Therapeutics Inc.] |
|
|
|
| Onxeo S.A. announced that it had received a Notice of Allowance from the US Patent and Trademark Office for a new patent in the United States covering the systemic administration of AsiDNA™ for the treatment of TNBC and chemo-resistant lung cancer, alone or in combination with chemotherapy, radiotherapy or other tumor DNA-damaging agents.
[Onxeo S.A.] |
|
|
|
| Recent studies have shown that Lunit’s artificial intelligence solution was as accurate as average radiologists when it came to identifying breast cancer.
[Lunit Inc (PRNewswire LLC)] |
|
|
|
|
|
|
| | German Cancer Research Center – Heidelberg, Germany |
|
|
|
| | University of Cambridge – Cambridge, United Kingdom |
|
|
|
| | Memorial Sloan Kettering Cancer Center – New York, New York, United States |
|
|
|
| | Brigham and Women’s Hospital, Harvard Medical School – Boston, Massachusetts, United States |
|
|
|
| | Fred Hutchinson Cancer Research Center – Seattle, Washington, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
